Ocrevus and Lenticular opacities - a phase IV clinical study of FDA data

Summary:

Lenticular opacities is reported as a side effect among people who take Ocrevus (ocrelizumab), especially for people who are female, 50-59 old, also take Dalfampridine, and have Primary progressive multiple sclerosis.

The phase IV clinical study analyzes which people have Lenticular opacities when taking Ocrevus. It is created by eHealthMe based on reports of 56,539 people who have side effects when taking Ocrevus from the FDA, and is updated regularly.

What is Ocrevus?

Ocrevus has active ingredients of ocrelizumab. eHealthMe is studying from 56,583 Ocrevus users. Check the latest studies of Ocrevus.

What is Lenticular opacities?

Lenticular opacities (swelling and opacity of the entire lens) is found to be associated with 75 drugs and 152 conditions by eHealthMe. Check the latest studies of Lenticular opacities.

On Jul, 11, 2026

56,539 people reported to have side effects when taking Ocrevus.
Among them, 12 people (0.02%) have Lenticular opacities.

Could Ocrevus cause Lenticular opacities?

Among these 12 people:

What is the gender of people who have Lenticular opacities when taking Ocrevus? *

female: 100 %
male: 0.0 %

What is the age of people who have Lenticular opacities when taking Ocrevus? *

What are other drugs people take besides Ocrevus? *

Levothyroxine Sodium: 5 people, 41.67%
Dalfampridine: 5 people, 41.67%
Alvesco: 1 person, 8.33%
Albuterol: 1 person, 8.33%

What are other side effects people have besides Lenticular opacities? *

Fatigue (feeling of tiredness): 9 people, 75.00%
White Blood Cell Count Decreased: 8 people, 66.67%
Tonsillitis (inflammation of tonsil): 8 people, 66.67%
Nasopharyngitis (inflammation of the nasopharynx): 8 people, 66.67%
Nearsightedness (difficulty in seeing the far objects): 8 people, 66.67%
Immunoglobulins Abnormal: 7 people, 58.33%
Nerve Compression: 5 people, 41.67%
Joint Pain: 5 people, 41.67%
Sleep Disorder: 5 people, 41.67%
Hypoaesthesia (reduced sense of touch or sensation): 4 people, 33.33%

What are the existing conditions these people have? *

Primary Progressive Multiple Sclerosis (primary progressive inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 8 people, 66.67%
Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 4 people, 33.33%

* Approximation only. Some reports may have incomplete information.

Do you take Ocrevus and have Lenticular opacities?

- Check whether Lenticular opacities is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ocrevus:

Ocrevus (56,583 reports)

Browse all side effects of Ocrevus:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Lenticular opacities:

Lenticular opacities (75 drugs)

Browse all the conditions that are associated with Lenticular opacities:

Lenticular opacities (152 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ocrelizumab (the active ingredients of Ocrevus) and Ocrevus (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.